Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya BioSciences, Inc. - Common Stock (NQ: AKYA )

1.500 +0.020 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akoya BioSciences, Inc. - Common Stock

< Previous 1 2 Next >
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
From Akoya Biosciences, Inc.
Via GlobeNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
From Quanterix Corporation
Via Business Wire
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports Third Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
KR-HT5 is based on Akoya’s PhenoImager® HT Platform 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback